1. Introduction {#s0005}
===============

The award of the 2016 Nobel Prize for Medicine or Physiology to Professor Yoshinori Ohsumi for his work on elucidating mechanisms of autophagy recognizes the importance of autophagy for human disease. Autophagy allows cells to maintain intracellular homeostasis and respond to stress by degrading proteins, organelles and other cellular components via the lysosome. This process is evolutionally conserved and acts as a critical cellular response to nutrient and oxygen deprivation, resulting in recycled amino acids, nutrients, and lipids. Alterations in autophagy and inherited mutations in autophagy related genes, known as *ATG* genes, that control autophagy have been linked to human disease, including neurological diseases, autoimmune disease, metabolic disorders, infectious disease and cancer. These connections imply that therapeutic interventions to boost or inhibit autophagy may be useful to treat or prevent disease ([@bb0455]). Here we review the roles of autophagy in two such diseases-- neurodegenerative disease and cancer-- where direct therapeutic targeting intended to stimulate and inhibit autophagy is moving forward in the clinic.

2. Opportunities to Target Autophagy for Therapy {#s0010}
================================================

Three types of autophagy have been characterized-- microautophagy, chaperone mediated autophagy (CMA), and macroautophagy. Microautophagy involves direct engulfument and lysosomal degradation of cytosolic material, ([@bb0210]) while CMA is facilitated by chaperones that target proteins containing a specific amino acid motif to the lysosome. Although CMA is implicated in disease ([@bb0065]), this review will focus on macroautophagy.

Macroautophagy (from here on termed autophagy) is characterized by the formation of double membrane vesicles called autophagosomes that engulf cytoplasmic material then fuse with the lysosome to degrade their contents. The process involves various steps: initiation, nucleation, elongation, and closure of the membranes that form the autophagosome, fusion with the lysosome and recycling of macromolecular precursors. Each step is regulated by particular autophagy-related proteins (ATGs) ([@bb0310]). Autophagy is controlled transcriptionally by MITF and FOXO families of transcription factors ([@bb0100]), as well as CREB and ATF ([@bb0010]) and is subject to post-translational regulation allowing its pharmacological manipulation both positively and negatively ([Fig. 1](#f0005){ref-type="fig"}). For example, the mammalian target of rapamycin (mTOR) complex, mTORC1 inhibits autophagy. Thus, mTOR inhibitors are often used to stimulate autophagy. mTORC2 has also been linked to autophagy, although this may be specific to CMA ([@bb0015]). Autophagy can also be induced independently of mTOR. For example, the naturally occurring disaccharide, trehalose, which works independently of mTOR ([@bb0475]), induces autophagy to protect against liver disease by affecting glucose transporters ([@bb0070]).

Other interventions inhibit autophagy, including inhibitors of the protein kinases, ULK1 and ULK2 ([@bb0085], [@bb0365]), and the class III phosphoinositide-3-kinase, (VPS34) ([@bb0025], [@bb0080], [@bb0425]). VPS34 is a component of the BCL-2 interacting moesin-like coiled-coil protein 1, (Beclin-1) signaling complex. Beclin-1 contains a BH3 domain, allowing it to interact with other BH3 containing proteins, including B cell CLL/lymphoma 2 (BCL-2), and the downstream functions of the Beclin-1 complex can differ with respect to autophagy, dependent on the molecules found in complex with it ([@bb0505]). Other components of the complex include ultraviolet irradiation resistant-associated gene (UVRAG), SH3GLB2, (also known as BIF-1), and activating molecule in Beclin-1 regulated autophagy 1 (AMBRA1). Some of these interactions can be pharmacologically targeted. BH3 mimetics like Venetoclax, which was designed to induce apoptosis by blocking BCL-2 interactions at the mitochondria, also disrupt interactions between Beclin-1 and BCL-2 to induce autophagy ([@bb0275]). However, this mechanism has been challenged and it has been proposed that BH3 mimetics may only affect autophagy via indirect mechanisms that occur sometime after they have hit their direct target ([@bb0415]). A cell-permeable peptide, Tat-Beclin1, disrupts another interaction in the Beclin-1 complex to induce autophagy ([@bb0495]). In addition to the many drugs that can modulate autophagy ([@bb0200]), non-pharmacological interventions including caloric restriction and exercise also induce autophagy. For example, exercise targets the Beclin-1 signaling complex to induce autophagy that can protect mice against diabetes ([@bb0120]). Two ubiquitin-like conjugation systems elongate the autophagosome membrane. The ubiquitin-like protein ATG12 is conjugated to ATG5 in a process requiring the E1-like enzyme, ATG7. A similar lipid conjugation system (also using ATG7) attaches phosphatidylethanolamine (PE) to the Microtubule Associated Protein 1 light chain 3 (MAP1LC3) and GABA type A receptor-associated protein (GABARAP) families of proteins. Pharmacological inhibitors of ATG7 that block these processes have been discussed at meetings. LC3-PE conjugation occurs after cleavage and processing of LC3 by the protease, ATG4B, which can also be inhibited pharmacologically ([@bb0005]). LC3-PE is incorporated into the autophagosome membrane and is the most common marker of autophagy ([@bb0170]). The final step is to fuse the autophagosome with the lysosome by the SNARE protein, STX17 ([@bb0125]). This step can be blocked with lysosomal inhibitors such as chloroquine (CQ) and hydroxychloroquine (HCQ) or Bafilomycin A1. Once fusion is complete, the lysosomal hydrolases degrade the contents of the autophagosomes producing amino acids, nutrients, and lipids that are available to fuel protein and other macromolecular synthesis and metabolism.

3. Targeting Autophagy in Neurological Diseases {#s0015}
===============================================

Autophagy has been implicated in neurodegenerative disease for two reasons. First, defects in autophagy cause neurodegeneration. For example, although systemic knockout of *Atg7* leads to neonatal death in mice ([@bb0175]), neuronal deletion allows the mice to survive to adulthood, however the animals succumb to neurodegenerative disease ([@bb0180]). Moreover, when *Atg7* is acutely deleted in all cells in adult animals, the most common cause of death is neurodegenerative disease with accumulation of ubiquitinated protein aggregates ([@bb0145]). A mutation in the human *ATG5* gene that inhibits autophagy also causes congenital ataxia and developmental delay ([@bb0165]). The second link to neurodegenerative diseases including Alzheimers Disease (AD), Parkinson\'s Disease (PD), and Huntington\'s Disease (HD) is the involvement of toxic protein aggregates that can be degraded via autophagy in the pathology of all of these diseases ([@bb0325]).

Alzheimer\'s disease is the most common progressive neurodegenerative dementia and is characterized by the accumulation of plaques and intra-neuronal fibrillary tangles, where the former consists of beta-amyloid peptides (Aβ) that are highly insoluble and toxic ([@bb0380]), and the latter is composed of hyperphosphorylated microtubule-associated protein TAU aggregates ([@bb0565]). Defective lysosomal proteolysis and compromised autophagosome transport occurs in AD resulting in an accumulation of autophagosomes as well as Aβ peptides and Tau protein aggregates ([@bb0625]).

Huntington\'s disease is an autosomal dominant disease caused by CAG repeat expansion in the portion of the gene containing several glutamines, known as the polyglutamine (Poly Q) tract of the *HTT* gene ([@bb0335]) and patients present with cognitive dysfunction and a loss of motor control thought to be due to toxic aggregates from the polyQ containing protein. Cytoplasmic aggregates formed by mutant forms of HTT (mHTT) can be removed by autophagy, and stimulation of autophagy with mTOR inhibitors, as well as mTOR independent autophagy inducers, can reduce neuronal toxicity in Huntington\'s disease models ([@bb0480]) ([Table 1](#t0005){ref-type="table"}). Autophagosomes in HD disease may also be defective and are often devoid of contents resulting in abnormal amounts of mHTT protein aggregates that are not degraded by the lysosome ([@bb0280]). Additionally, mHTT itself affects autophagy resulting in accumulation of autophagosomes that are unable to fuse with lysosomes ([@bb0595]).

Accumulation of α-synuclein (SNCA) defines the molecular pathology of Parkinson\'s disease, a progressive disorder that results from the death of dopaminergic neurons in the substantia nigra. Patients accumulate Lewy bodies, intracytoplasmic inclusions containing SNCA, which act as a neurotoxin. Macroautophagy, CMA, as well as mitophagy (i.e. selective autophagy of mitochondria) have all been implicated in PD ([@bb0325], [@bb0330]). Notably, Pink1 and Parkin, two proteins whose loss of function is directly linked to Parkinson\'s disease, also help facilitate the removal of damaged mitochondria by the process of mitophagy, and loss of this process resulting in an accumulation of dysfunctional mitochondria has been shown to be causative for the disease ([@bb0450]). Additionally, loss of autophagy results in increased oxidative stress, which exacerbates PD pathology ([@bb0535]).

In light of these and other studies suggesting that autophagy plays a cytoprotective role against neurodegenerative diseases ([@bb0460]), a number of interventions to enhance autophagic flux, that is the fusion of lysosomes and autophagosomes and degradation of autophagosome cargo, have been tested ([Table 1](#t0005){ref-type="table"}). One study shows that in an animal model of AD, the Vitamin B precursor, Nicotinimide could reduce Aβ and hyperphosphorylated Tau as well as improve cognitive performance, all dependent on restoration of autophagy ([@bb0240]). Resveratrol inhibits rotenone-induced dopaminergic neuron cell death in a model of PD ([@bb0235]). Because the effects were abrogated by an autophagy inhibitor this is thought to be due to autophagy. mTOR inhibitors such as rapamycin and CCI-779 can induce autophagy to improve motor neuron functioning in fly and mouse models of HD ([@bb0405]). Consequently, several compounds including many that feed into mTOR signaling are moving forward towards clinical trials for different diseases ([Table 1](#t0005){ref-type="table"}). One such class of drugs antagonize the G-protein coupled receptor, 5-HT~6~R, known to activate mTOR signaling in the brain ([@bb0295]), and include the compounds AVN-211 ([@bb0130]) ([@bb0320]) (Phase IIa clinical trial for Schizophrenia, highlighting safety), Lu AE58054 (AKA idalopirdine)([@bb0585])(Phase III clinical trial for AD - [NCT02006641](ctgov:NCT02006641){#ir0160}, [NCT02006654](ctgov:NCT02006654){#ir0165}, [NCT02079246](ctgov:NCT02079246){#ir0170}), and SB-742457([@bb0270]) (Phase II clinical trial for AD- NCT00224497, NCT0034819, [NCT00708552](ctgov:NCT00708552){#ir0175}, [NCT00710684](ctgov:NCT00710684){#ir0180}).

There are caveats with the above mentioned studies. First, there is no good method for accurately quantifying autophagy in vivo, and especially in human patients. This makes it difficult to be sure that drugs that increase autophagic flux in cultured cells are also doing so in vivo. Second, agents that activate autophagy also have other effects, for example mTOR inhibitors also affect protein, nucleotide, and lipid synthesis as well as glutamine metabolism and glycolysis all via autophagy independent mechanisms ([@bb0215]). This makes it difficult to know if the beneficial effects are due to increased autophagy or other effects. An advantage in preclinical models is the ability to design controlled experiments where an intervention intended to increase autophagy is also tested in animals with a separate genetic interference of autophagy, which should abrogate the protective effects seen by the intervention. However, this kind of experiment is also subject to criticism; it may show that autophagy is necessary for protection against disease but doesn\'t necessarily mean that the increase in autophagy is responsible. A major hurdle for the field is to develop better ways to stimulate autophagy in a more specific manner. In summary, while more work is needed to fully elucidate the mechanisms of these compounds and their therapeutic potential, upregulation of autophagy remains a promising therapeutic approach for neurodegenerative diseases such as Alzheimer\'s, Parkinson\'s and Huntington\'s disease.

4. Targeting Autophagy in Cancer {#s0020}
================================

Most clinical studies that are attempting to therapeutically target autophagy are in cancer. A recent search of [ClinicalTrials.Gov](http://ClinicalTrials.Gov){#ir0185} using the search term "autophagy" brought up over 60 clinical trials, of which \> 50 are cancer trials attempting to inhibit autophagy. This is somewhat surprising because, unlike with neurodegenerative diseases where the consensus view is that autophagy protects against disease, autophagy can both promote and inhibit tumor growth and autophagy\'s roles vary in different context ([@bb0580]).

Autophagy was first suggested to be a tumor suppressor when a study from Beth Levine\'s group ([@bb0220]) found that Beclin-1 interacts with an oncogenic protein (BCL-2) and some breast, prostate, and ovarian cancer tumors had a monoallelic loss in *BECN1* (encoding Beclin-1). In human tumors, these results are complicated by close proximity of the *BECN1* gene and the potent tumor suppressor *BRCA1* ([@bb0185], [@bb0540]). This makes it difficult to rule out the possibility that in human tumors, it is loss of *BRCA1* rather than *BECN1* that is important. Indeed, TCGA data shows there is no significant loss of *BECN1* independent of *BRCA1* loss ([@bb0580]). In mice, monoallelic deletion of the *Becn1* gene alone is sufficient to cause mammary hyperplasia, ([@bb0375], [@bb0620]) with possible context-specific effects with different oncogenic drivers ([@bb0055]). However, the *Becn1*^*+/−*^ genotype still maintains functional autophagy, while other autophagy knockouts that are much more systemically deficient in autophagy ([@bb0615]) do not develop cancer suggesting that the *Becn1*^*+/−*^ tumor phenotype may be autophagy independent. Mutation of other autophagy regulators (e.g. the UVRAG ([@bb0225]), BIF1 ([@bb0060]), and AMBRA proteins ([@bb0050])) that are all in the Beclin-1 complex have also been implicated in cancer. However, all of these molecules and Beclin1 itself also have autophagy independent roles. These complications mean that it is possible that some tumor suppressor effects of Beclin1 and other components of the complex are actually due to autophagy-independent functions.

In KRAS-driven mouse models, knockout of *Atg5* or *Atg7* often promotes pre-malignant lesions ([@bb0395], [@bb0440], [@bb0610],). KO of *Atg5* delays the onset of lung cancer in KRAS-driven model of lung cancer, although once tumors do progress, *Atg5* loss enhances survival ([@bb0395]). Likewise, in a KRAS-driven pancreatic cancer model, loss of *Atg5* or *Atg7* accelerates tumor initiation but blocks malignant progression ([@bb0440]). Although not fully understood, both these studies also demonstrated a role for TP53 in switching between pro and anti-tumorigenic roles of autophagy. A recent study found that mutations in a splicing factor increased cell transformation by incorrectly processing the *ATG7* mRNA resulting in decreased ATG7 protein and defective autophagy ([@bb0345]), again suggesting that autophagy protects against early steps in tumor development. Taken together, these various studies suggest that autophagy may play a role in suppressing tumor initiation but can promote tumor progression. Consistent with this idea, genetic enhancement of autophagy (by overexpression of active TFEB, a master transcriptional regulator of autophagy) can increase growth of established tumors ([@bb0575]).

In vitro studies using shRNAs to target \> 100 autophagy regulators identified a number of breast cancer cell lines that are dependent upon functional autophagy for growth even in the absence of stress ([@bb0290]). Importantly however, some tumor cell lines were barely affected by autophagy gene knockdown indicating that tumor cells differ greatly in their dependence on autophagy. This work followed studies suggesting that cancer cell lines with mutant RAS genes are "autophagy addicted" ([@bb0105]) and some tumor types, e.g. pancreas cancer, which transcriptionally induces high levels of autophagy ([@bb0360]), are highly dependent on autophagy ([@bb0605]). However, RAS mutation alone does not determine sensitivity to autophagy inhibition in vitro ([@bb0315]) highlighting the need for more rigorous studies to identify which tumor cells are, or are not, autophagy-dependent.

Similarly, in vivo studies have indicated the necessity of *Atg5* or *Atg7* in KRAS- or BRAF-driven tumor models ([@bb0145], [@bb0395], [@bb0440], [@bb0610], [@bb0110], [@bb0530], [@bb0600]). A requirement for autophagy to maintain tumors in vivo has also been demonstrated for cancers driven by PTEN loss ([@bb0465]). Moreover, additional autophagy regulators such as FIP200, have been shown to maintain tumor growth due to autophagy and not other functions of the protein ([@bb0045]). One caveat for many of the mouse studies is that deletion of the *Atg* gene occurs simultaneously with activation of the oncogenic driver and occurs only in the tumor cells. These experiments do not adequately model what autophagy inhibition would be like in the clinic. A patient would likely only be treated after they had a full-blown cancer with an autophagy inhibitor that cannot discriminate between autophagy in the cancer cells and autophagy in the rest of the body. This has been modeled in KRAS-driven lung cancer, where tumors were allowed to develop before systemic loss of the *Atg7* gene was achieved ([@bb0145]). Complete, irreversible inhibition of autophagy by *Atg7* deletion in adult mice caused death by bacterial infection or, after several weeks, neurodegeneration and the animals displayed defects in glucose homeostasis and extreme sensitivity to starvation. However, these results also indicate a therapeutic window where the tumor can be eradicated without wholesale toxicity when autophagy is inhibited. The existence of such a therapeutic window-- a given dose and/or length of treatment time that can be effective in inhibiting tumor growth without overt toxicity, provides an opportunity for therapeutic inhibition. In the clinic we would likely never have a drug that is as good at inhibiting autophagy as complete knockout of an *ATG* gene. Moreover, autophagy inhibition with a drug could be reversed by removing the drug, thus this work tells us that even a "perfect" autophagy inhibitor might not be so toxic that it couldn\'t be used in cancer therapy.

As with its tumor suppressing roles, the mechanisms by which autophagy supports tumor growth are poorly understood. Autophagy has been implicated in the pro-tumorigenic processes of glycolysis, oxidative metabolism, cell proliferation and anchorage-independent growth ([@bb0245], [@bb0550]). In addition autophagy is involved in metastasis ([@bb0150]). For example, it is important in tumor cell invasion and migration, and metastasis in vivo due to autophagy induced focal adhesion disassembly ([@bb0155], [@bb0485]) and autophagy-regulated cytokine secretion ([@bb0250]). Autophagy deficiency in cancer cells results in multiple metabolic problems and the accumulation of defective mitochondria ([@bb0115]). Additionally autophagy in stromal cells can promote tumor cell metabolism by feeding amino acids (specifically alanine) to the tumor cells ([@bb0515]). It is likely that a combination of metabolic effects and other cellular functions such as cytokine secretion contribute to autophagy\'s ability to promote tumor growth and progression and thus explain how, for some tumors, autophagy inhibition alone can have profound anti-cancer effects.

Autophagy also plays a role in response to treatment. An extensive literature suggests that autophagy can protect cancer cells against commonly used cancer therapies including a wide array of different drugs and radiation ([@bb0545], [@bb0410]). Such studies are the basis for most of the current efforts to target autophagy in patients ([Table 2](#t0010){ref-type="table"}). Perhaps even more important than chemo-sensitization, autophagy inhibition may overcome acquired resistance to other anti-cancer agents. The best evidence for this is in tumors with activating mutations in BRAF that have become resistant to BRAF inhibitors like vemurafenib. Vemurafenib resistance in melanoma is associated with increased autophagy and autophagy inhibition can reverse resistance associated with endoplasmic reticulum stress ([@bb0255]). There is also evidence that autophagy inhibition to overcome drug resistance can be effective in patients. A brain cancer patient with a BRAF mutant tumor that had become resistant to vemurafenib was successfully treated with a combination of CQ and vemurafenib experiencing long term tumor regression on the combination treatment ([@bb0205]). Importantly, this patient had periods of time when the autophagy inhibitor CQ was maintained but the BRAF inhibitor was discontinued for periods of time. In every instance, this led to increased tumor growth that was reversed when the combination treatment was re-established. This case study is the first to suggest that autophagy inhibition with CQ can overcome acquired resistance to the kinase inhibitor but that only combination treatment with both the BRAF inhibitor and the autophagy inhibitor is effective. Continued follow up of this patient has demonstrated sustained tumor regression for over two and a half years and more recent studies submitted for publication from Mulcahy-Levy et al. have extended these findings to two other patients both of whom acquired resistance to vemurafenib following successful therapy and then experienced clinical improvement on the combination of CQ and vemurafenib.

Although most current clinical trials ([Table 2](#t0010){ref-type="table"}) involve autophagy inhibition, there are arguments against this idea often revolving around effects of autophagy inhibition on the immune response to cancer ([@bb0630]). It has been reported that "immunogenic" tumor cell killing-- i.e. killing cancer cells with chemotherapy in a way that will lead to effective engagement of an anti-tumor immune response -- requires that the dying cancer cells have functional autophagy ([@bb0305]) leading to suggestions that we should try to enhance autophagy to improve cancer immunotherapy ([@bb0630]). Consistent with this idea, a recent study concluded that caloric restriction could enhance tumor immunosurveillance only for autophagy-proficient tumors ([@bb0370]). However, autophagy inhibition can enhance immune cell-mediated, anti-tumor effects under at least some circumstances ([@bb0230], [@bb0020]). More work is needed to better understand the interplay between autophagy\'s role(s) in the anti-tumor immune response.

5. Clinical Trials of Targeted Autophagy Inhibition {#s0025}
===================================================

Despite the caveats discussed above, there are already many studies attempting to inhibit autophagy in cancer therapy. All the current studies use CQ or HCQ. These drugs inhibit the lysosome and block autophagy while causing accumulation of autophagosomes and LC3, which have been used as pharmacodynamic markers of the inhibitor\'s activity. CQ and HCQ are inexpensive, approved drugs that have been used for decades to treat malaria and arthritis but have some caveats as autophagy inhibitors. First, they can have anti-tumor effects through other mechanisms such as reducing nutrient scavenging and can sensitize to other chemotherapies by autophagy-independent mechanisms ([@bb0090], [@bb0285]). Second, alterations in tumor pH may affect drug bioavailability ([@bb0355]).

Clinical trials targeting multiple neoplasms have been launched to assess the effects of autophagy inhibition in combination with radiation, conventional cytotoxic chemotherapies and targeted agents including DNA damaging agents, HDAC inhibitors, proteasome inhibitors, mitotic inhibitors, antiandrogens, and several kinase inhibitors ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0190}, [Table 2](#t0010){ref-type="table"}). Additional studies in melanoma, glioblastoma, pancreatic, breast, lung, and prostate cancer are testing CQ/HCQ as a single agent (ClinicalTrials.gov). A major caveat with the current clinical trials is that we have no way to identify patients who are most likely to benefit. At least initially, one strategy to do this may be to focus on tumors with mutations that confer sensitivity to autophagy inhibitors like the BRAF mutant brain tumor studies mentioned above ([@bb0205]).

The first Phase I and I/II trials have been reported testing autophagy inhibition alone or in combination with a proteosome inhibitor (bortezomib), radiation therapy, DNA damaging agents, i.e. temazolomide and doxorubicin, as well as the mTOR inhibitor, temsirolimus, and the HDAC inhibitor vorinostat ([@bb0435], [@bb0390], [@bb0385], [@bb0030], [@bb0265], [@bb0560], [@bb0590], [@bb0420], [@bb0350]). Doses effective for autophagy inhibition can be reached with minimal side effects, although one study in glioblastoma patients did report grade 3 and 4 neutropenia and thrombopenia ([@bb0435]). Thus far, no studies have reported adverse side effects expected of autophagy inhibition based on pre-clinical animal studies, such as increased incidence of neuropathy, secondary cancers, infections, or metabolic disturbances. Encouragingly, some studies suggest favorable clinical responses. Rangwala et al. reported a partial response and stable disease in 14% and 27%, respectively, of metastatic melanoma patients treated with HCQ in combination with temozolomide, with a complete response and prolonged stable disease seen in 2/6 patients with WT BRAF refractory melanoma ([@bb0390]). Moreover, a phase II study of CQ and radiation therapy on brain metastasis in patients with advanced solid tumors report progress free survival after one year in 84% of patients as compared to 55% of patients in the control arm (radiation therapy alone) ([@bb0420]).

6. Outstanding Questions {#s0030}
========================

In this article we have focused on just two types of disease (neurodegenerative disease and cancer) where different approaches to therapeutically manipulate autophagy have been adopted and where clinical studies are underway. However there are still many outstanding questions even for just these two areas. For example, although there is considerable evidence that autophagy inhibition can make other anti-cancer drugs more effective, this may only apply in tumor cells that start off being dependent on autophagy. Indeed, in cancer cells that are not autophagy-dependent the same drug combination may be antagonistic rather than synergistic ([@bb0205], [@bb0290]); we are currently unable to predict if cancer cells will or won\'t be autophagy-dependent. Some drugs are also thought to require autophagy in order to kill cancer cells ([@bb0545]). In neurodegenerative diseases it is unclear whether or not different ways of activating autophagy will be more or less effective and we are greatly hampered by the fact that even for laboratory studies we lack good tools to specifically activate autophagy without affecting other cellular processes. In cancer therapy we have poor understanding of when autophagy will increase tumor cell killing and when it will decrease it and we need to better understand the interplay between autophagy and the immune response to cancer. For any therapy involving autophagy manipulation, a major problem is our inability to accurately measure autophagic flux in vivo to assess if the intervention actually worked.

Given the competing roles described above, an important question is whether treatment of cancer by autophagy inhibition will lead to neurodegenerative side effects and likewise, that treatment of neurodegenerative diseases with autophagy promoting agents might promote pre-malignant tumors. There are currently no studies that specifically induce autophagy, making it difficult to address the risk of autophagy inducing agents. However, because activities like exercise and caloric restriction that induce autophagy systemically ([@bb0120], [@bb0370]) are known for their health advantages, we speculate that specific autophagy induction may be safe. We must also consider the role of autophagy manipulation intended to treat one disease on other systems and organs, such as the liver ([@bb0260]).

7. Concluding Remarks {#s0035}
=====================

A danger is that if clinical studies of therapeutic targeting of autophagy are ineffective, it may be because of our lack of knowledge about who to treat and how best to manipulate autophagy and not because autophagy manipulation is an ineffective therapy. It would be a pity if autophagy-targeted therapies were abandoned when the problem was that we didn\'t fully understand their effects rather than that autophagy manipulation was never going to be effective. As with many areas of biology where competing effects are seen-- e.g. the immune system can both promote and inhibit tumorigenesis while affecting a multitude of other diseases, the key to successful implementation of therapies designed to target a specific process lies in understanding the biology and trying to specifically target the processes you want to enhance or inhibit. Continued progress on understanding how autophagy affects diseases like cancer and neurodegeneration and the development of better ways to manipulate and measure these processes should hopefully allow us to maximize the potential for autophagy manipulation to treat disease.

Search strategy and selection criteria: Data for this review were obtained from PubMed searches using the criteria: "autophagy and cancer", "Huntington\'s disease", "Parkinson\'s disease", and "Alzheimer\'s disease". Clinical trial information was obtained from [Clinicaltrials.gov](http://Clinicaltrials.gov){#ir0155} using the search criteria: "autophagy", "chloroquine", and "hydroxychloroquine". Only articles published in English from 1993 to 2016 were included with particular emphasis on studies from 2014 to 2016.

![Interventions that target autophagy. Macroautophagy is controlled by nutrient availability via regulation by mTORC1, which under conditions of nutrient availability can inhibit the formation of Ulk1/2 complexes. Ulk complexes facilitate Beclin-1 complex formation and phagaphore initiation. Phagaphore elongation is then mediated by LC3-PE conjugation and ATG5-12 conjugation. Finally, double membrane autophagasomes fuse with lysosomes to form autophagolysosomes resulting in degradation of autophagosome contents by lysosomal hydrolases. A number of pharmacological and naturally occurring agents have been designed/discovered that target this pathway allowing interventions that upregulate and down regulate autophagy.](gr1){#f0005}

###### 

Compounds that directly/indirectly upregulate autophagy in neurodegenerative diseases.

Table 1

  Disease                         Compound                                  Mechanism                                               Model tested/clinical trial phase   Reference
  ------------------------------- ----------------------------------------- ------------------------------------------------------- ----------------------------------- -------------
  Alzheimer\'s                    AVN-211                                   Antagonist of 5-HT~6~R (mTOR activator)                 Rodent models                       ([@bb0130])
  Lu AE58054 (AKA idalopirdine)   Antagonist of 5-HT~6~R (mTOR activator)   Phase III                                               ([@bb0585])                         
  SB-742457                       Antagonist of 5-HT~6~R (mTOR activator)   Phase II                                                ([@bb0270])                         
  AUTEN-67                        MTMR-14 (autophagy inhibitor)             *Drosophilia*, Zebrafish and preclinical rodent model   ([@bb0340])                         
  rAAV/Aβ vaccine                 AKT/mTOR                                  Rodent models                                           ([@bb0570])                         
  ACAT1                           Unknown                                   Neuroblastoma cells and rodent models                   ([@bb0490])                         
  Rapamycin                       Antagonist to mTOR                        Rodent models                                           ([@bb0040], [@bb0500])              
  Nicotinamide                    Lysosomal acidification                   Phase I                                                 ([@bb0240])                         
  Resveratrol                     Antagonist to TORC1                       Phase III                                               ([@bb0555])                         
  Lithium                         AMPK                                      Phase II                                                ([@bb0095])                         
  Latrepirdine                    Antagonist to mTOR                        Phase III                                               ([@bb0525])                         
  Metformin                       Antagonist to mTOR/PP2A                   Phase II                                                ([@bb0160])                         
  Parkinson\'s                    DMF                                       Activation of NRF2                                      Rodent models                       ([@bb0190])
  Curcumin                        TFEB                                      Rodent models                                           ([@bb0135], [@bb0510])              
  BECN1 gene                      Beclin-1 complex                          Rodent model                                            ([@bb0520])                         
  TFEB gene                       TFEB regulation                           Rodent model                                            ([@bb0075])                         
  Huntington\'s                   AUTEN-67                                  MTMR-14                                                 *Drosophila*                        ([@bb0035])
  Rapamycin/CCI-779               Antagonist to mTOR                        *Drosophila* and Rodent models                          ([@bb0405])                         
  Berberine                       Unknown                                   Rodent models                                           ([@bb0140])                         
  Rheb gene                       Activator of mTOR                         Rodent models                                           ([@bb0195])                         
  Calpastatin                     Calpain inhibitor                         Rodent models                                           ([@bb0300])                         
  Rilmenidine                     Unknown                                   Rodent models                                           ([@bb0430])                         
  Trehalose                       Unknown                                   Rodent models                                           ([@bb0470])                         

###### 

Active and recently completed clinical trials (last 2 years) with autophagy inhibition for the treatment of cancer.

Table 2

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Tumor type                                                Clinical trial phase   Drug combination                                                                                               Reference
  --------------------------------------------------------- ---------------------- -------------------------------------------------------------------------------------------------------------- -------------------------------------------
  Breast                                                    Phase II               CQ + Taxols (microtubule inhibitors)                                                                           [NCT01446016](ctgov:NCT01446016){#ir0005}

  Breast                                                    Phase II               CQ                                                                                                             [NCT02333890](ctgov:NCT02333890){#ir0010}

  Breast (DCIS\*)                                           Phase I/II             CQ                                                                                                             [NCT01023477](ctgov:NCT01023477){#ir0015}

  Pancreatic                                                Phase I                CQ + gemcitabine                                                                                               [NCT01777477](ctgov:NCT01777477){#ir0020}

  Pancreatic                                                Phase I/II             HCQ + gemcitabine                                                                                              [NCT01506973](ctgov:NCT01506973){#ir0025}

  Pancreatic                                                Phase II               HCQ + gemcitabine (DNA damaging) + abraxane (microtubule inhibitor)                                            [NCT01978184](ctgov:NCT01978184){#ir0030}

  Pancreatic                                                Phase I/II             HCQ + gemcitabine (DNA damaging)                                                                               [NCT01128296](ctgov:NCT01128296){#ir0035}

  Melanoma                                                  Phase I                CQ + radiation + DT01 (DNA repair inhibitor)                                                                   [NCT01469455](ctgov:NCT01469455){#ir0040}

  Melanoma                                                  Phase I/II             HCQ + Trametinib (MEK inhibitor)                                                                               [NCT02257424](ctgov:NCT02257424){#ir0045}

  Small cell lung                                           Phase I                CQ                                                                                                             [NCT00969306](ctgov:NCT00969306){#ir0050}

  Small cell lung                                           Phase I                CQ + radiotherapy                                                                                              [NCT01575782](ctgov:NCT01575782){#ir0055}

  Non-small cell lung                                       Phase II               HCQ + Paclitaxol (mycrotubule inhibitor) + carboplatin (DNA damaging) + Bevacizumab (angiogenesis inhibitor)   [NCT01649947](ctgov:NCT01649947){#ir0060}

  Colorectal                                                Phase I/II             HCQ + Oxaliplatin (alylating) + 5-FU (DNA damaging) + Bevacizumab (angiogenesis inhibitor)                     [NCT01206530](ctgov:NCT01206530){#ir0065}

  Colorectal                                                Phase II               HCQ + Bevacizumab (angiogenesis inhibitor) + XELOX (Alkylating + antimetabolite)                               [NCT01006369](ctgov:NCT01006369){#ir0070}

  Colorectal                                                Phase II               HCQ + Vorinostat (HDAC inhibitor)                                                                              [NCT02316340](ctgov:NCT02316340){#ir0075}

  Prostate                                                  Phase II               HCQ + ABT-263 (Bcl inhibitor) + Abiraterone (antiandrogen)                                                     [NCT01828476](ctgov:NCT01828476){#ir0080}

  Prostate                                                  Phase II               HCQ                                                                                                            [NCT00726596](ctgov:NCT00726596){#ir0085}

  Renal cell carcinoma                                      Phase I/II             HCQ + RAD001 (mTOR inhibitor)                                                                                  [NCT01510119](ctgov:NCT01510119){#ir0090}

  Glioblastoma, astrocytoma                                 Phase II               CQ + chemoradiation with temezolomide (alkylating agent)                                                       [NCT02432417](ctgov:NCT02432417){#ir0095}

  Glioma, chondrosarcoma, intrahepatic cholangiocarcinoma   Phase I/II             CQ + Metformin                                                                                                 [NCT02496741](ctgov:NCT02496741){#ir0100}

  Glioblastoma                                              Phase I                CQ + chemoradiation with temezolomide (alkylating agent)                                                       [NCT02378532](ctgov:NCT02378532){#ir0105}

  Brain metastasis                                          Not provided           CQ + radiotherapy                                                                                              [NCT01727531](ctgov:NCT01727531){#ir0110}

  Adult solid neoplasm                                      Phase I                HCQ + Sunitinib Malate (RTKi)                                                                                  [NCT00813423](ctgov:NCT00813423){#ir0115}

  Multiple myeloma                                          Phase II               CQ + Velcade (protease inhibitor) + Cyclophosphamide (alkylating agent)                                        [NCT01438177](ctgov:NCT01438177){#ir0120}

  Relapsed solid tumors                                     Phase I                HCQ + Sorafenib (RTKi)                                                                                         [NCT01634893](ctgov:NCT01634893){#ir0125}

  Advanced solid tumors                                     Phase I                HCQ + MK2206 (Akt inhibitor)                                                                                   [NCT01480154](ctgov:NCT01480154){#ir0130}

  Solid tumors                                              Phase I                CQ + carboplatin/gemcitabine (DNA damaging)                                                                    [NCT02071537](ctgov:NCT02071537){#ir0135}

  Advanced cancers                                          Phase I                HCQ + vorinostat (HDAC inhibitor)\                                                                             [NCT01266057](ctgov:NCT01266057){#ir0140}
                                                                                   HCQ + Sirolimus (mTOR inhibitor)                                                                               

  Solid tumor                                               Phase I                HCQ + vorinostat (HDAC inhibitor)                                                                              [NCT01023737](ctgov:NCT01023737){#ir0145}

  Adult solid tumor                                         Phase I                HCQ + temsirolimus                                                                                             [NCT00909831](ctgov:NCT00909831){#ir0150}
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
